Journal of Managed Care & Specialty Pharmacy

Article	Citations
Direct medical costs of obesity in the United States and the most populous states	110
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States	18
Complication-specific direct medical costs by body mass index for 13 obesity-related complications: a retrospective database study	15
Burden of hospitalization for heart failure in the United States: a systematic literature review	14
Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis	13
Racial disparities in medication use: imperatives for managed care pharmacy	13
Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: A systematic literature review	13
Validation of EHR medication fill data obtained through electronic linkage with pharmacies	12
Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies	12
Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data	12
Direct health care costs associated with COVID-19 in the United States	11
All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States	11
Pharmacists as accessible health care providers: quantifying the opportunity	11
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs	10
Economic value of nonsurgical weight loss in adults with obesity	10
Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes	10
Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis	10
Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis	10
Impact of financial medication assistance on medication adherence: a systematic review	10
The effectiveness and value of aducanumab for Alzheimer’s disease	10
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective	9
Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease	9
Use of real-world evidence in economic assessments of pharmaceuticals in the United States	9
Health care resource utilization and costs associated with atrial fibrillation and rural-urban disparities	9
Healthcare resource utilization and cost among patients with type 1 diabetes in the United States	9

Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population	9
Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries	9
Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States	8
Polypharmacy is a risk factor for mortality, severe chronic kidney disease, and liver disease among privately insured adults with cerebral palsy	8
Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States	8
Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation	8
Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy	8
The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States	8
Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis	8
Procurement and use of social determinants of health data among key health care stakeholders	8
Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis	8
Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression	7
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system	7
Improving patient-reported measures in oncology: a payer call to action	7
Drugs likely subject to Medicare negotiation, 2026-2028	7
Trends in off-label use of antipsychotic medications among Texas Medicaid children and adolescents from 2013 to 2016	7
The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis	7
Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy	7
Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder	7
Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database	7
Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States	7
COVID-19 vaccination and race – A nationwide survey of vaccination status, intentions, and trust in the US general population	6
Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018	6
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States	6
Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use	6
Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system	6
The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review	6
Payer perceptions of the use of real-world evidence in oncology-based decision making	6
Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis	6
Effect of clinical pharmacist interventions on cost in an integrated health system specialty pharmacy	6
Decision makers need an approach to determine digital therapeutic product quality, access, and appropriate use	6
Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene–related peptide inhibitors vs other preventive migraine treatments in the United States	6
Factors associated with medication nonadherence among Medicare low-income subsidy beneficiaries with diabetes, hypertension, and/or heart failure	6
Increased health care costs associated with new persistent opioid use after major surgery in opioid-naive patients	6
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States	5
The economic burden of Parkinson disease among Medicare beneficiaries	5
Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare s	5
Estimated discounts generated by Medicare drug negotiation in 2026	5
Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer	5
Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis	5
Cost of epilepsy-related health care encounters in the United States	5
Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis	5
Economic and utilization outcomes of medication management at a large Medicaid plan with disease management pharmacists using a novel artificial intelligence platform from 2018 to 2019: a retrospectiv	5
Few new drugs deserve expedited regulatory treatment	5
Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States	5
The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma–based severity levels: Insights from a large US commercial and managed Medicaid population	5
Mavacamten for hypertrophic cardiomyopathy: effectiveness and value	5
Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs	5
Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States	5
The effectiveness and value of novel acute treatments for migraine	5

Economic burden of growth hormone deficiency in a US pediatric population	5
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations	5
Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma	5
Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States	5
Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology	5
Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review	5
Statin use and mortality in rheumatoid arthritis: an incident user cohort study	5
Specialty drug and health care utilization vary by wage level in employer-sponsored health plans	4
Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies	4
Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration	4
Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative	4
Relationships between headache frequency, disability, and disability-related unemployment among adults with migraine	4
Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States	4
Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit	4
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations	4
The direct and indirect costs of adult atopic dermatitis	4
Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis	4
Medications for obesity management: Effectiveness and value	4
The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective	4
Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims	4
Need for payer-provider partnerships in addressing social determinants of health	4
Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting	4
Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States	4
Trends in add-on medications following metformin monotherapy for type 2 diabetes	4
The effectiveness and value of novel treatments for cystic fibrosis	4
The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD	4
The role of integrated medical and prescription drug plans in addressing racial and ethnic disparities in medication adherence	4
Performance-based pharmacy payment models: key components and critical implementation considerations for successful uptake and integration	4
Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis	4
The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease	4
Correlation between medication adherence using proportion of days covered and achieving viral suppression in patients living with HIV	4
AMCP Pay-for-Performance Principles: Performance-Based Reimbursement and Direct and Indirect Remuneration (DIR) Fees	4
Association between multiple sclerosis disease severity and adherence to disease-modifying therapies	4
Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study	4
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis	4
Proposal for capturing patient experience through extended value frameworks of health technologies	4
Health care costs and resource use of managing hemophilia A: A targeted literature review	4
International reference pricing for prescription drugs: a landscape analysis	3
Oral treatments for outpatient COVID-19: Effectiveness and value	3
Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma	3
Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study	3
Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study	3
Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases	3
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars	3
Cardiorenal disease in the United States: Future health care burden and potential impact of novel therapies	3
Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility	3
Methodology for conducting a comprehensive product review in managed care	3
Burden of illness among patients with dementia-related psychosis	3
Association of 3 CDC opioid prescription guidelines for chronic pain and 2 payer pharmacy coverage changes on opioid initiation practices	3
Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value	3
Annual costs among patients with major depressive disorder and the impact of key clinical events	3
Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?	3
Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia	3
Real-world analysis of insurance churn among young adults with schizophrenia using the Colorado All-Payer Claims Database	3
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies	3
Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs	3
Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States	3
Use of prescriber requirements among US commercial health plans	3
COVID-19 and adherence to biologic therapies for psoriasis: An analysis of nationwide pharmacy claims data	3
Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results–Medi	3
A systematic review of the real-world effectiveness and economic and humanistic outcomes of selected oral antipsychotics among patients with schizophrenia in the United States: Updating the evidence a	3
Alignment of diagnosis and pharmacy claims data coding of medication adherence among patients with diabetes or hypertension	3
Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer	3
Social determinants of health and adult influenza vaccination: a nationwide claims analysis	3
JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value	3
Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insure	3
Self-reported adherence and reasons for nonadherence among patients with low proportion of days covered for antihypertension medications	3
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions	3
Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes	3
Addressing racial inequality and its effects on vaccination rate: A trial comparing a pharmacist and peer educational program (MOTIVATE) in diverse older adults	3
The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Ad	3
Racial and ethnic disparities due to Medicare Part D Star Ratings criteria among kidney transplant patients with diabetes, hypertension, and/or dyslipidemia	3
The impact of biosimilar insulins on the diabetes landscape	3
Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 3	3
Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatme	3
Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab	3
Stakeholders find that step therapy should be evidence-based, flexible, and transparent: assessing appropriateness using a consensus approach	3
For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports	3
Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective	3
Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements	3

Association of dyskalemias with short-term health care utilization in patients with advanced CKD	3
Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States	3
Comparing total medical expenditure between patients receiving direct oral anticoagulants vs warfarin for the treatment of atrial fibrillation: evidence from VA-Medicare dual enrollees	3
Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate	3
Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals	3
Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis	3
Navigating changes in Clostridioides difficile prevention and treatment	3
Social needs of dual-enrolled Medicare-Medicaid patients with medication nonadherence in a telehealth medication therapy management program	3
Health care costs and utilization prior to diagnosis of antineutrophil cytoplasmic antibody vasculitis in Medicare beneficiaries	2
Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy	2
Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation	2
A primer on brand-name prescription drug reimbursement in the United States	2
A harm reduction model to assess the impact of new treatments for pain over standard of care among patients with osteoarthritis	2
The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities	2
Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspectiv	2
Barriers, solutions, and effect of using pharmacogenomics data to support opioid prescribing	2
Specialty pharmacy turnaround time impediments, facilitators, and good practices	2
Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage	2
Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration–approved solid tumor therapies, 1995-2021	2
Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States	2
The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities	2
It is time for a new comprehensive medication review quality measure	2
The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum	2
Clinical and economic impact of primary hyperoxaluria: a retrospective claims analysis	2
A primer on managed care pharmacy	2
Racial Disparities in Medication Use: JMCP’s Response and Call for Submissions	2
Cost sharing: implications of a well-intended benefits strategy	2
The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer	2
Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model	2
Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis	2
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study	2
The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors	2
Design and effect of performance-based pharmacy payment models	2
Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis	2
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analys	2
The patient’s medication access journey: a conceptual framework focused beyond adherence	2
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma	2
Changes in Schedule II oral opioid volume dispensed in a private health plan following Florida’s Acute Pain Opioid Restriction Law	2
Using latent class and quantum models to value equity in health care: a tale of 2 stories	2
A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model	2
Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States	2
Financial burden associated with discordance to intravenous iron therapies in US patients with iron deficiency anemia	2
Advancing a managed care pharmacy research agenda: Generating real-world evidence to support US Food and Drug Administration Accelerated Approvals and improving benefit design to address health inequi	2
Evaluation of a pharmacist-driven medication adherence enhancement service	2
Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study	2
Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder	2
A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective	2
Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy	2
The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia	2
Prescription drug coverage satisfaction, cost-reducing behavior, and medication nonadherence among Medicare beneficiaries with type 2 diabetes	2
Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis	2
Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States	2
Health insurance coverage and switching among people with hemophilia A in the United States	2
A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?	2
Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs	2
Racial/ethnic and gender disparities in the use of erythropoiesis-stimulating agents and blood transfusions: cancer management under Medicare’s reimbursement policy	2
Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population	2
Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience	2
Best practices in designing preapproval information engagements for US health care decision makers	2
Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes	2
Ensuring a high-quality and resilient supply chain of essential medications means paying more	2
Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients	2
Drug-dispensing limits within Medicaid during the COVID-19 pandemic	2
The effects of patient out-of-pocket costs for insulin on medication adherence and health care utilization in patients with commercial insurance; 2007-2018	2
Health care resource utilization and costs among individuals with vs without Huntington disease in a US population	2
Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines	2
Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non–small cell lung cancer	2
Evaluating perceptions of social determinants of health and Part D star performance of Medicare Advantage-contracted primary care providers serving a South Texas market	2
Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States	2
The impact of a statewide insulin copay cap policy for insured patients with diabetes in Utah	2
Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs	2
Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis	2
A prediction model for nonpersistence or nonadherence to direct oral anticoagulants in hospitalized patients with atrial fibrillation	2
US health care utilization and costs in adult patients with atopic dermatitis by disease severity	2
Poster Abstracts - Academy of Managed Care Pharmacy 2023	2
Effect of the ExactCare medication care management model on adherence, health care utilization, and costs	2
Association between health system specialty pharmacy use and health care costs among national sample of Medicare Advantage beneficiaries	2
Qualitative exploration of factors influencing the plan selection process by Medicare beneficiaries	2
The impact of opioid prescribing report cards in Medicaid	2
The effectiveness and value of belimumab and voclosporin for lupus nephritis	2
An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database	2
The effectiveness and value of tezepelumab for severe asthma	2
Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective	2
Is it time to replace the star ratings adherence measures?	2
Does access to free medication reduce health system costs? An evaluation of the Dispensary of Hope program	2
The cost impact of disease progression to metastatic castration-sensitive prostate cancer	2
Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia	2
Characterizing health plan evidence review practices	2
Indication or diagnosis should be required on prescriptions	2
Poster Abstracts - Academy of Managed Care Pharmacy 2022	2
Comparing the burden of illness in patients with alopecia areata vs atopic dermatitis in the US population from a payer perspective	2
Using the Delphi method to identify meaningful and feasible outcomes for pharmaceutical value-based contracting	2
Economic burden of multiple sclerosis in the United States: A systematic literature review	2
Prescription digital therapeutics: Applying Medicaid experience to value assessment and formulary management	2
The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders	2